Aktienanalyse zu VivoSim Labs Inc (VIVS)VIVSVivoSim Labs Inc

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models. It operates in the Healthcare sector.

VivoSim Labs Inc (VIVS) is not a good buy right now due to its significant financial struggles and poor technical indicators. The current price is $0.14, which is near its 52-week low of $0.14, and the stock has experienced a staggering year-to-date change of -92.45%. Additionally, the RSI is at 35.34, indicating that the stock is oversold, but this does not guarantee a price recovery. The company has reported substantial losses, with a net income of -$5,764,000 in Q4 2026 and a gross margin of 100%, but this has not translated into profitability. The main risk is the company's high volatility and lack of consistent revenue growth, as evidenced by a 20-day change of -21.15%.